Reread your last sentence again and consider it from a different...

Reread your last sentence again and consider it from a different point of view.

Is Dr Andrew Saich only transferring his skills to IRX, or is the game plan for him to transfer the whole proposed trial that he planned at Senzer?

Look at how neatly all the pieces overlap if we take a more complete look at his Linkedin:

The proposed Senzer trial was for:

1. inhaled pharmaceutical-grade cannabinoid inhalers
2. the treatment of specific medical conditions with a requirement for immediate symptom relief
3. a CBD, a THC and a combined CBD/THC inhaler to meet US/EU regulatory standards .

The trial but was abandoned due to a lack of funding; i.e., is IRX being set up to fund his trials?

Sounds like a lot of the work has already been done, too:

"Clinical development plans were drawn-up for a CBD, a THC and a combined CBD/THC inhaler to meet US/EU regulatory standards."

Anyway who cares because Dr Andrew Saich is probably just a loser who was made redundant?

Except if we scroll down a little further on his Linkedin we can see:
Medical Director - Epilepsy and Neuroscience
GW Pharmaceuticals plc
May 2016 - Sep 2019

Isn't this the giant company (bought for USD$ 7billion by Jazz Pharma) IHL is aspiring to be?

If we stitch it altogether, I'd argue IRX is positioning itself to fund a trial for an unmet medical need that requires immediate symptom relief, most likely in epilepsy or neuroscience (or both).

I also disagree with you that Sud (IHL AUD$700 million) alone is insufficient for IRX to be likened as a company. I'd back Dr Sud 8 days a week to get the job done.

But when add in Dr Saich (GW Pharma USD$ 7billion) and Vijay Sappani (TerrAscend USD$ 1.2 billion), you have a trinity of proven winners in the medical cannabis space, well supported by a capable and growing team.

Who in their right mind would bet against this trinity?

If my thesis proves correct, to borrow a quote from @Chaya "don't say I didn't warn you."

Imho